At the 2014 American Society of Hematology (ASH) Annual Meeting, Prof Marek Trn?ný (Charles University Hospital, Prague, Czech Republic) discusses the phase 2 SPRINT (MCL-002) study of lenalidomide versus investigators choice in relapsed or refractory mantle cell lymphoma, including the study design; efficacy and safety endpoints; and conclusions.
This programme has been supported by sponsorship from Celgene
Advertisement Single Between Content
Advertisement Single Between Content
Advertisement Single Between Content
Advertisement Single Below Content
Advertisement Single Below Content
Advertisement Single Below Content